32 results about "Bone metabolism disorder" patented technology

The present invention provides liquid formulations of antibodies or antibody fragments that immunospecifically bind to integrin αVβ3, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of the antibodies or antibody fragments, even during long periods of storage. In particular, the present invention provides liquid formulations of antibodies or fragments thereof that immunospecifically bind to integrin αVβ3, which formulations are substantially free of surfactant, inorganic salts, and / or other common excipients. Furthermore, the invention provides methods of preventing, treating or ameliorating an inflammatory disorder, an autoimmune disorder, a disorder associated with aberrant expression and / or activity of integrin αVβ3, a disorder associated with abnormal bone metabolism, a disorder associated with aberrant angiogenesis or cancer utilizing the liquid formulations of the present invention.

Provided is a pharmaceutical composition for the treatment and / or prophylaxis of abnormal bone metabolism targeting a protein encoded by a gene strongly expressed in osteoclasts. Specifically provided is a pharmaceutical composition containing an antibody which specifically recognizes human Siglec-15 and has an activity of inhibiting osteoclast formation, and the like.

Novel bisphosphonate cyclic acetal compounds are disclosed, as well as methods of preparing the compounds, pharmaceutical compositions including the compounds, and administration of the compounds in methods of treating bone metabolism disorders, such as abnormal calcium and phosphate metabolism.

A compound or its salts that inhibit the activity of the polypeptide or receptor of the present invention and the antibody of the present invention as well as the antisense DNA of the present invention are useful as, e.g., gastric acid secretion inhibitors, mucosa protectants, mineral absorption promoters, etc., which are less toxic and safe, and can be used as, e.g., agents for preventing / treating upper digestive tract disorders, antibacterial agents to Helicobacter pylori, etc. A compound or its salts that promote the activity of the polypeptide or receptor of the present invention, the polypeptide or receptor of the present invention and the DNA of the present invention can be used as, e.g., gastric acid secretion promoters and can be used as, e.g., agents for preventing / treating dyspepsia, bone metabolism disorders, anemia, etc. A compound or its salts that promote the activity of the polypeptide or receptor of the present invention, the polypeptide of the present invention, etc. can also be used as test agents for gastric secretory function. Furthermore, the polypeptide or receptor of the present invention and the DNA of the present invention are also useful for screening the agents for the prevention / treatment described above.

The present invention discloses a calcium-phosphorus mixture and its application. Its composition is formed from (by wt%) 1.2%-2.2% of calcium and 0.4%-0.67% of phosphorus. Said calcium-phosphorus mixture can be used for preparing food, health-care product or medicine for inhibiting bone absorption, promoting bone formation and curing bone metabolic abnormality due to PTH deficiency.

The present invention provides compositions and methods for providing controllable local delivery of a conjugate of chloroquine (CQ) and a bisphosphonate to treat diseases characterized by abnormal bone metabolism. In certain embodiments, the invention is used as a treatment for a subject with diseases and disorders characterized by bone loss.

It is intended to provide a preventive agent or a therapeutic agent for a disease caused by abnormal bone metabolism, particularly for osteoporosis, which is more effective than ever before. By combined application of N-hydroxy-4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)-phenoxy]pentoxy}-benzamidine or a salt thereof and one or more compounds selected from the group consisting of etidronic acid, clodronic acid, pamidronic acid, tiludronic acid, risedronic acid, minodronic acid, ibandronic acid, zoledronic acid, and salts thereof, a higher bone resorption inhibitory action compared with the administration of a single compound is exhibited, and an excellent preventive effect and therapeutic effect for a disease caused by abnormal bone metabolism, particularly for osteoporosis can be obtained.

The invention discloses asiaticoside, and a function of a pharmaceutically acceptable derivative thereof in bone metabolic abnormality. The asiaticoside has an adjustment function on simultaneously inhibiting osteoclast formation under the situation of bone metabolic abnormality, is low in effective dosage, and has a better effect on adjusting bone metabolic abnormality. The invention defines an intervention way of an asiaticoside related drug. The invention clarifies that a molecular mechanism in a bone microenvironment and a potential pharmacology intervention way are crucial to identifyinga novel treatment compound.

Disclosed is a therapeutic or prophylactic agent for diseases associated with abnormal bone metabolism, particularly osteoporosis, which is more effective than conventional therapeutic or prophylactic agents. Specifically disclosed is a combination of an N-hydroxybenzamidine derivative represented by formula (I) or a salt thereof and active vitamin D or a prodrug thereof, which has a superior therapeutic or prophylactic effect on diseases associated with abnormal bone metabolism, particularly osteoporosis, compared with that achieved by the administration of the N-hydroxybenzamidine derivative or a salt thereof or the active vitamin D or a prodrug thereof alone.